AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$BLTE

Chuang Hao-Yuan sold $12.8M of BLTE

Chuang Hao-Yuan (Chief Financial Officer) sold 67,395 shares of BELITE BIO, INC (BLTE) at an average of $189.98 ($180.16–$198.05, $12.80M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chuang Hao-Yuan
Published Sep 9, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
medium confidence
Mentioned
$BLTE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishLow
01

Why it matters

The insider sell could be interpreted as a negative signal, but the pre‑arranged nature tempers the impact.

02

Market read

Primary insider sale with material dollar amount; modest trading relevance for BLTE.

03

What to watch

No immediate catalyst; the CFO may be diversifying personal portfolio.

Relevance 6/10Novelty 8/10Timing: post filing today

Background

Form 4 filings disclose insider transactions; a $12.8M sale by the CFO is a primary source event.

Company-level read

Ticker impact

$BLTEBearishMedium confidence
Context

CFO Chuang Hao-Yuan sold 67,395 shares for $12.8M via a 10b5‑1 plan, reducing his stake to 26,038 shares.

Expected impact

Potential downward pressure over the next few trading sessions.

Evidence & confidence

The sale size ($12.8M) is material for a micro‑cap biotech and was executed under a pre‑arranged plan, suggesting a neutral to bearish signal.

Market effects

Sector

May raise concerns for other biotech micro‑caps with insider sales.

Regional

Limited to U.S. OTC biotech segment.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, possibly unrelated to company outlook.

Key entities

  • Company
    Belite Bio, Inc.

    Biotech firm listed under ticker BLTE.

  • Executive
    Chuang Hao-Yuan

    Chief Financial Officer of Belite Bio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min